Preparation method for difunctional nanoparticle carrier and preparation method for difunctional nanoparticle preparation
A nanoparticle, dual-function technology, which can be used in pharmaceutical formulations, medical preparations with non-active ingredients, and medical preparations containing active ingredients, etc. Encapsulation efficiency, the effect of good performance
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0039] This embodiment relates to a preparation method of a bifunctional nanoparticle carrier PLGA-PEG-Folate;
[0040] The synthesis of bifunctional nanoparticle carrier PLGA-PEG-Folate specifically includes the following steps:
[0041] (1) Using HO-PEG-OH as raw material, NH was synthesized in three steps 2 -PEG-NH 2 , the synthesis process is as figure 1 Shown, NH 2-PEG-NH 2 of 1 HNMR results such as figure 2 shown;
[0042] (2) with CH 2 Cl 2 As a solvent, react the activated PLGA-COOH with p-hydroxybenzaldehyde, and then add the catalyst p-toluenesulfonic acid to undergo a condensation reaction to form a PLGA derivative with a hydrazone bond (-NH-N=CH-), and synthesize Process such as image 3 As shown, the PLGA derivatives with hydrazone bonds 1 HNMR results such as Figure 4 shown;
[0043] (3) After activation of the carboxyl terminal of the PLGA derivative with a hydrazone bond, use DMF as solvent, DCC\NHS as catalyst, and NH 2 -PEG-NH 2 The acylation...
Embodiment 2
[0045] This embodiment relates to a preparation method of a bifunctional nanoparticle preparation loaded with vincristine sulfate;
[0046] The preparation of the bifunctional nanoparticle preparation loaded with vincristine sulfate comprises the following steps:
[0047] (1) Vincristine sulfate was dissolved in Tris-HCl buffer solution at pH 6.8 to form a concentrated solution (referred to as phase I), and PLGA-mPEG and bifunctional nanoparticle carrier PLGA-PEG-Folate (the mass of both ratio of 8:1) dissolved in an organic solvent (dichloromethane or acetone) (called phase II), the volume ratio of Tris-HCl buffer solution to organic solvent is 1: (5-20), vincristine sulfate administration The amount is 10%~15% (w / w);
[0048] (2) Under the condition of ultrasonic ice bath, add phase I dropwise to phase II to obtain colostrum;
[0049] (3) Under the condition of ultrasonic ice bath, add Tris-HCl buffer solution containing 0.6% to 2% PVA (w / v) and pH 5 to 7.4 dropwise into c...
Embodiment 3
[0054] This embodiment relates to a preparation method of PLGA-mPEG nanoparticles;
[0055] The preparation method is the same as in Example 1 and Example 2 to obtain PLGA-mPEG nanoparticle preparation NP1.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More - R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com
